The Short-term Efficacy of Novel NTDP-RFA in the Treatment of Small HCC With Cirrhosis.

NCT04513119 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2020-08-14

No results posted yet for this study

Summary

To evaluate the short-term efficacy of novel no-touch combined directional perfusion radiofrequency ablation in the treatment of small hepatocellular carcinoma with cirrhosis.

Conditions

  • Hepatocellular Carcinoma Stage I
  • Radiofrequency Ablation

Sponsors & Collaborators

  • Southwest Hospital, China

    lead OTHER

Principal Investigators

  • Kuansheng Ma, Ph.D · Institute of hepatobiliary surgery,Southwest Hospital

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2022-07-01
Completion
2022-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04513119 on ClinicalTrials.gov